BiTE for acute myeloid leukemia (AML) targets proteins expressed on most AML blasts, such as CD33 and CD123, and cell surface proteins that are often overexpressed or mutated on AML blasts, such as FLT3 [72]. This evidence concerns the gene FLT3 and acute myeloid leukemia.